The AI-driven cancer progression risk analytics framework (AI CanPRAF) is developed, which integrates AI taxonomies, imaging phenotypes, clinical context, progression analytics and decision support into one clinically oriented model.
Abstract
Artificial intelligence (AI) has emerged as a transformative analytical paradigm for modelling cancer progression using medical imaging and complementary clinical data. This systematic review collates and analyses AI-powered systems and techniques for cancer progression risk analytics and prediction. It provides an empirical examination of algorithmic approaches, imaging-derived feature domains, and clinical metrics that underpin progression prediction. Following the PRISMA 2020 reporting guidance, empirical English-language studies published between 2020 and the final search cutoff date of 15 May 2026 were identified from PubMed, EBSCOhost, Google Scholar and Web of Science. Forty (40) eligible studies spanning diverse cancer types were included, appraised using the MMAT and synthesised narratively. The evidence shows that both classical machine learning models and deep learning architectures are widely used to extract predictive information from radiological data. Radiomic descriptors of intratumoural heterogeneity, tumour morphology, functional imaging biomarkers and multiscale transform-based features consistently demonstrate strong associations with disease progression. Imaging-derived features were linked to clinically meaningful progression endpoints, including progression-free survival, disease-free survival, recurrence and metastasis, while clinical and molecular covariates supported risk stratification. This study further develops the AI-driven cancer progression risk analytics framework (AI CanPRAF), which integrates AI taxonomies, imaging phenotypes, clinical context, progression analytics and decision support into one clinically oriented model. The results demonstrate the growing role of multimodal AI systems in the development of clinically grounded cancer progression analytics and prediction solutions.
The study crafts an evidence-informed conceptual 5Fs framework comprising feature extraction or generation, feature preparation and transformation, feature selection and dimensionality reduction, feature construction and integration, and feature interpretability and explainability that highlights the feature-centric na...
Wellington Kanyongo, B. Chimbo· Informatics· 0 citations
Background/Objectives: Computational and artificial intelligence (AI)-enabled imaging biomarkers are increasingly being investigated for immunotherapy-response assessment in oral squamous cell carcinoma (OSCC), but the evidence is heterogeneous. This systematic review identified, critically appraised, and synthesized i...
Carlos M. Ardila, A. M. Vivares-Builes, Eliana Pineda-Vélez· Medical Science· 0 citations
This review synthesizes key developments in ML for oncology, covering foundational algorithms alongside emerging approaches, and describes future directions, including federated learning, graph neural networks, longitudinal modeling, and integration of real-world and wearable data to support precision oncology.
Kanishk Yadav, Taneesha Gupta· Journal of the Egyptian Nati...· 0 citations
This review critically evaluates how advanced technologies operating in an integrated manner facilitate precision oncology by supporting fields such as genomics, transcriptomics, proteomics, metabolomics, and radiomics and provides an integrative roadmap for modern, multiomics-driven biomarker approaches in precision o...
Ujwal Havelikar, Atharva A. Shinde, Hrushikesh Mhaismale et al.· Omics· 0 citations
Conventional genomic biomarkers remain central to current lung cancer treatment decisions because of their established clinical validity, and AI-based genomic models show promise for improving prediction and patient stratification, but their clinical utility remains uncertain without stronger prospective validation.
F. Siddique, M. Shehata, M. Ghazal et al.· Oncology Research· 0 citations
Emerging AI paradigms offer future-ready frameworks for personalized, privacy-preserving oncology care and multi-omics integration powered by AI enables the discovery of robust biomarkers for diagnosis, prognosis, and therapy response prediction.
M. Anwer, Krupa R. Bhaliya, Ming Q. Wei· Translational Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.